Company news

Olema Pharmaceuticals, Inc. news in 2024

Olema Pharmaceuticals, Inc.'s news releases, calls and decks from 2024, newest first.

View company

Olema Oncology Presents Updated Clinical Results for Palazestrant in Combination with Ribociclib at the San Antonio Breast Cancer Symposium

December 9, 2024

Olema Oncology Announces FDA Clearance of Investigational New Drug Application for OP-3136, a Potent KAT6 Inhibitor

December 8, 2024

Olema Oncology Announces New Clinical Trial Collaboration and Supply Agreement with Novartis in Frontline Metastatic Breast Cancer as well as $250 Million Equity Private Placement

December 1, 2024

Olema Oncology to Present New Data Combining Palazestrant with Ribociclib at the San Antonio Breast Cancer Symposium

November 24, 2024

Olema Oncology Reports Third Quarter 2024 Financial Results and Provides Corporate Update

November 11, 2024

Olema Oncology Presents Compelling New Preclinical Data Demonstrating Anti-Tumor Activity for OP-3136 with Enhanced Activity of Palazestrant Combinations at ENA 2024

October 22, 2024

Olema Oncology Announces New Preclinical Combination Data to be Presented at the 2024 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

October 8, 2024

Olema Oncology to Participate in Morgan Stanley 22nd Annual Global Healthcare Conference

August 20, 2024

Olema Oncology Reports Second Quarter 2024 Financial Results and Provides Corporate Update

August 5, 2024

Olema Oncology to Participate in Upcoming Investor Conferences in June

May 27, 2024

Olema Oncology Announces Promising New Data for Palazestrant in Combination with Ribociclib Presented at the 2024 ESMO Breast Cancer Congress

May 14, 2024

Olema Oncology Reports First Quarter 2024 Financial Results and Provides Corporate Update

May 7, 2024

Olema Oncology Announces New Clinical Data for Palazestrant in Combination with Ribociclib to be Presented at the 2024 ESMO Breast Cancer Annual Congress

May 7, 2024

Olema Oncology to Participate in Upcoming Investor Conferences in May

April 30, 2024

Olema Oncology to Participate in Canaccord Genuity 2024 Horizons in Oncology Virtual Conference

April 7, 2024

Olema Oncology Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Corporate Update

March 10, 2024

Olema Oncology Announces Publication of Data Highlighting Palazestrant’s Ability to Inhibit Wild-Type and Mutant ER+ Breast Cancer Both as Monotherapy and in Combination with CDK4/6 Inhibitors

March 5, 2024

Olema Oncology Nominates OP-3136, an Orally Bioavailable KAT6 Inhibitor, as a Development Candidate

January 7, 2024

Olema Oncology to Present at 42nd Annual J.P. Morgan Healthcare Conference

January 1, 2024

Decks in 2024